A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Tazemetostat (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 05 Dec 2017 Planned End Date changed from 1 Nov 2018 to 1 Sep 2018.
- 05 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jan 2017 New trial record